The Use of Patient-Reported Outcome Measures in Phase I Oncology Clinical Trials

Objective: To investigate patient-reported outcome (PRO) usage in phase I oncology clinical trials, including types of PRO measures and changes over time. Methods: We analyzed ClinicalTrials.gov records of phase I oncology clinical trials completed by December 2019. Results: Of all eligible trials, 2.3% (129/5,515) reported ≥1 PRO, totaling 181 instances of PRO usage. PRO usage increased over time, from 0.6% (trials initiated before 2000) to 3.4% (trials starting between 2015 and 2019). The most common PRO measures were unspecified (29%), tumor-specific (24%), and generic cancer (19%). Conclusion: Although uncommon in phase I oncology clinical trials, PRO usage is increasing over time. PRO measures were often unspecified on ClinicalTrials.gov, suggesting that more precise reporting and standardization are needed.

[1]  L. Watson,et al.  Validating a Patient-Reported Outcomes-Derived Algorithm for Classifying Symptom Complexity Levels Among Patients With Cancer. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

[2]  Arlene E. Chung,et al.  Feasibility and delivery of patient-reported outcomes in clinical practice among racially diverse bladder and prostate cancer patients. , 2020, Urologic oncology.

[3]  S. Montgomery,et al.  African Immigrant Health: Prostate Cancer Attitudes, Perceptions, and Barriers , 2020, American journal of men's health.

[4]  B. Hobbs,et al.  Reprioritizing Risk and Benefit: The Future of Study Design in Early-Phase Cancer Research. , 2019, Ethics & human research.

[5]  K. Getz,et al.  Evaluating the Completeness of ClinicalTrials.gov , 2019, Therapeutic innovation & regulatory science.

[6]  F. Fiteni,et al.  Health-related quality of life as an endpoint in oncology phase I trials: a systematic review , 2019, BMC Cancer.

[7]  A. Gnanasakthy,et al.  A Review of Patient-Reported Outcomes Labeling for Oncology Drugs Approved by the FDA and the EMA (2012-2016). , 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[8]  M. Stockler,et al.  The importance of patient-reported outcomes in clinical trials and strategies for future optimization , 2018, Patient related outcome measures.

[9]  T. Mullin,et al.  Enhancing the incorporation of the patient’s voice in drug development and evaluation , 2018, Research Involvement and Engagement.

[10]  Joanna Coast,et al.  Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension , 2018, JAMA.

[11]  E. Basch,et al.  Patient-reported outcome measurement in drug discovery: a tool to improve accuracy and completeness of efficacy and safety data , 2016, Expert opinion on drug discovery.

[12]  Sandra A Mitchell,et al.  Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). , 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[13]  Amy P Abernethy,et al.  Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). , 2015, JAMA oncology.

[14]  A. Gnanasakthy,et al.  Inclusion of patient-reported outcome measures in registered clinical trials: Evidence from ClinicalTrials.gov (2007-2013). , 2015, Contemporary clinical trials.

[15]  Laura A. Levit,et al.  American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatment. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Isabelle Boutron,et al.  Timing and Completeness of Trial Results Posted at ClinicalTrials.gov and Published in Journals , 2013, PLoS medicine.

[17]  R. Polomano,et al.  Comparison Between Patient-Reported and Clinician-Observed Symptoms in Oncology , 2013, Cancer nursing.

[18]  Yuan Ji,et al.  Modified toxicity probability interval design: a safer and more reliable method than the 3 + 3 design for practical phase I trials. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  K. Flaherty,et al.  Modifying phase I methodology to facilitate enrolment of molecularly selected patients. , 2013, European journal of cancer.

[20]  Xavier Paoletti,et al.  Efficiency of New Dose Escalation Designs in Dose-Finding Phase I Trials of Molecularly Targeted Agents , 2012, PloS one.

[21]  M. Cazzola,et al.  Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. , 2012, Blood.

[22]  C. Garnett,et al.  U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with Intermediate and High-Risk Myelofibrosis , 2012, Clinical Cancer Research.

[23]  Lesley Seymour,et al.  An Overview of the Optimal Planning, Design, and Conduct of Phase I Studies of New Therapeutics , 2010, Clinical Cancer Research.

[24]  Razelle Kurzrock,et al.  Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse , 2010, Clinical Cancer Research.

[25]  Alexia Iasonos,et al.  Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. , 2009, Journal of the National Cancer Institute.

[26]  D. Patrick,et al.  The use of patient-reported outcomes instruments in registered clinical trials: evidence from ClinicalTrials.gov. , 2009, Contemporary clinical trials.

[27]  I Judson,et al.  Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter? , 2009, British Journal of Cancer.

[28]  E. Shaw,et al.  Patient-reported outcomes in phase II cancer clinical trials: lessons learned and future directions. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  U. S. Department of Health and Human Services FDA Cen Research,et al.  Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance , 2006, Health and quality of life outcomes.

[30]  R. Willke,et al.  Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[31]  D. Osoba,et al.  Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  D. Osoba,et al.  Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  M J Buxton,et al.  Evaluating patient-based outcome measures for use in clinical trials. , 1998, Health technology assessment.